Skip to main content

Table 1 Concurrent pembrolizumab and RT (n = 21)

From: Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

Characteristic   Median (range) or n (%)
Patient characteristic
 Female 7 (33%)
 Male 14 (67%)
Age at diagnosis of BM, y 67 (32-84)
Melanoma-specific GPA score 3 (1-4)
Karnofsky performance status 90 (80-90)
Median no. of BM treated w/SRS 1.5 (1-5)
Median BM diameter (maximum axial), cm 1.0 (0.2 - 2.4)
No. with non-brain metastases 19/21
No. with prior systemic therapy 13/21
  Ipilimumab 10/13
No. with BRAF directed therapy 5/21
No. with elevated LDH 3/12
Treatment characteristic
 No. with single fraction SRS 11 (52%)
  21 Gy, # lesions 19
  20 Gy, # lesions 1
  18 Gy, # lesions 3
No. with post-op RT (5 treatments) 7 (33%)
No. with whole brain RT 3 (14%)
Pembrolizumab dosage
  2 mg/kg 18 (86%)
  10 mg/kg 3 (14%)
No. of pembro doses 6.5 (1-38)